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Abstract. In this whitepaper, the Manufacturing Technical Committee (MTC) of the Product Quality
Research Institute has updated the 1997 Transdermal Drug Delivery Systems Scale-Up and Post Approval
Change workshop report findings to add important new product development and control principles.
Important topics reviewed include ICH harmonization, quality by design, process analytical technologies,
product and process validation, improvements to control of critical excipients, and discussion of Food and
Drug Administration’s Guidance on Residual Drug in Transdermal and Related Drug Delivery Systems as
well as current thinking and trends on in vitro–in vivo correlation considerations for transdermal systems.
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INTRODUCTION
In 1997, three scientific organizations, the American
Association of Pharmaceutical Scientists, the Food & Drug
Administration (FDA), and the United States Pharmacopeia
(USP) collaborated to organize a workshop to explore the
Scale-Upa n dPost Approval Change (SUPAC) principles for
AdhesiveTransdermalDrugDeliverySystems(TDS).The1997
SUPAC Workshop was the fourth in a series. Previous work-
shops covered other major pharmaceutical dosage forms; name-
ly, oral solid dosage forms, extended release oral dosage forms,
and semisolid and liquid topical dosage forms. The findings of
the Transdermal Dosage Form Workshop followed the estab-
lished SUPAC format of discussing the impact of (1) formula-
tion or compositional changes, (2) process variable changes, (3)
process scale changes, and (4) process site changes on the fin-
ishedquality parameters of the transdermal products. Each
area of change was further divided to reflect a hierarchy
of “significance” and hence aided in establishing post approval
change filing documentation.
Although the findings of the workshop were published
(1), unlike the outcome of prior workshop publications, the
findings of the TDS Workshop did not result in the publication
of a guidance document for use by both the pharmaceutical
industry and the worldwide regulatory communities. For this
reason, and also because the passage of time has introduced a
number of important innovations and practices for use in both
in-process and finished product control, it is timely to revisit
and update the TDS Workshop findings.
It is the hope of the authors that the updated information
presented herein will be useful to those in the industry
involved in the development of such products in presenting
comprehensive Chemistry, Manufacturing and Controls
(CMC) information to the USA and international regulatory
bodies involved in the review of the TDS dossier. It is our further
hope that the added information will lead to improved submis-
sion review times and approvals. While much of this information
is not contained in any “official guidance document” it should
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original submission Pharmaceutics Development Report
and aid in developing and justifying post approval change
submissions as well.
This whitepaper, sponsored by the Product Quality
Research Institute, is a result of that thinking and is designed to
engender additional discussion and commentary from other
experts within the industry, academia and worldwide regulatory
bodies. Although the document retains the spirit of the original
TDS Workshop report it encourages the inclusion of new tools
for the development, testing and control of TDS. The use of such
tools and approaches as process analytical technologies (PAT),
qualitybydesign(QbD),invitro–invivocorrelation(IVIVC)and
excipient characterization should improve the robustness of the
finished TDS and minimize or prevent unintended drift in the
quality of the commercial drug product.
REVIEW OF 1997 TDS WORKSHOP REPORT
FINDINGS
It is important to note that this whitepaper follows the
same convention as the 1997 TDS Workshop Report in that it
reviews passive TDS only. While, we, the authors recognize
the development and advent of active TDS, we feel that a
discussion of these is best left for a subsequent whitepaper as
the potential array of active systems is sufficiently broad to
warrant its own discussion. Our definition of “passive”
systems is any system that uses only nonfacilitated flux
to deliver drug to the stratum corneum; that is, they
exclude facilitated systems involving physical approaches
such as mechanical force, electrical force, heat, and sound.
We begin our 2011 TDS whitepaper with a brief review of
the salient findings of the 1997 publication.
Compositional Variables
In 1997, it was recognized that “transdermal delivery sys-
temstypicallycontain,inadditiontothedrug(s),vehiclessuchas
oils, alcohols, glycerin, water, fatty acid esters, surfactants, and
may also contain fillers or excipients such as lactose, silicone
dioxide, cellulose and cross-linking agents”(1). Furthermore it
was recognized that “the TDS platform will contain several
materials such as backing film, peelable liner, etc.w h i c hh a v e
inherent lot to lot variation and may influence drug release,
product wearability or product stability” (1). The passage of
time has certainly confirmed the truth of these statements and
therefore argues in favor of an updating of the TDS Workshop
principles based on current scientific thinking and capability.
The authors have undertaken to do this in the section of this
whitepaper entitled Improvements in Control of Critical Exci-
pients (see “Glossary” for definition) wherein, both traditional
excipients such as adhesives, viscosity agents, permeation
enhancers as well as release membranes and other critical com-
ponents are discussed.
In regards to compositional variables, the 1997 TDS Work-
shop Report concluded: “no ap r i o r iallowable range in exci-
pients or platform materials was established by the workshop
group” (1). The Workshop Report concludes: “…that for each
TDS, the development report should identify those excipients/
componentswhichhaveminorimpactonsystemfunctionalityor
performance and those that are critical” (1). We note in this
update that current technology allows improved identification,
testing, and control of these critical compositional components.
We also feel that the use of the current improved statistical
design packages when combined with QbD approaches can
affordsubstantialinformationabouttheallowablerangeofboth
minor excipients/components and those that are critical to the
TDS. In addition, the use of these approaches when combined
with improved testing techniques associated with PAT and
enhanced finished product testing such as in vitro release
can and should be used to facilitate review and approval
of post-approval TDS CMC submissions involving compo-
sitional variables. Each of these techniques will be discussed
fully in subsequent sections of this whitepaper.
Process Variables
Since 1997, substantial progress has been made by the
pharmaceutical industry in the development of robust manu-
facturing processes. Techniques such as PAT are becoming
more common in process control of manufacturing operations
and in continual feedback and feedforward loops that adjust
manufacturing operations thereby providing more consistent
end product. In parallel, improvements to end-product testing
have further increased the ability of companies to manufac-
ture more consistent products and to monitor and control
variation. Improvements to in-process and finished product
testing were anticipated in the 1997 Workshop Report which
recognized the value of “control of unit operations” and the
“characterization of the interplay between process variables
and end-product performance”, especially, “drug delivery”,
and “adhesion and wearability” (1). Our experts have
elaborated on these control strategies in several sections
of this whitepaper; notably those on process analytical
technology approaches, and, improvements to test methods
and controls of transdermal delivery systems. The latter topic
provides an update on improvements to testing of drug flux,
drug release, adhesionand tackiness, and,finally, in vitro/in vivo
correlations approaches.
In Vitro Tests
In vitro testing was common in 1997 and was regarded as
“a basic quality control tool used along with stability data to
control scale-up and post-approval changes” (1). In this
whitepaper, we review modernization of those techniques
and the testing equipment used to monitor drug flux, drug
release, adhesion, tackiness, and IVIVC.
In Vitro/In Vivo Correlation
The 1997 Workshop Report stated that three possible in
vitro/in vivo correlations could be investigated; those being: in
vitro release/in vivo skin permeation, in vitro release/in vivo
bioavailability, and in vitro permeation/in vivo bioavailability
(1). At that time, the authors concluded “there are very few
recordedinvitro/invivocorrelationsfortransdermalsystems…”
Since that time, the USP has published several updates to the
general chapter Drug Release <724>,a n dan u m b e ro fd r u g
product manufacturers have added specifications to the drug
product monographs describing drug release.
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attempted and submitted in vitro/in vivo correlations has not
increased. In fact, there is no published information indicating
that an IVIVC has been established for any currently mar-
keted passive transdermal system. Nevertheless, the authors
of this whitepaper have included current thinking about the
application of IVIVC in this update.
CURRENT PRINCIPLES THAT AFFECT TDS
DEVELOPMENT
Impact of ICH Harmonization
Since the 1997 Workshop article, various International
Conference on Harmonization (ICH) guidelines have issued
to help globally harmonize technical requirements for the
manufacture and use of active pharmaceutical ingredients
(APIs) and drug products. Of specific interest are: ICH Q8
(R2) entitled “Pharmaceutical Development” initially final-
ized in November 2005 (Revision 2 published in November
2009) (http://www.fda.gov/downloads/Drugs/Guidance
ComplianceRegulatoryInformation/Guidances/UCM073507.
pdf), ICH Q9 entitled “Quality Risk Management” published
in June 2006 (http://www.fda.gov/downloads/Drugs/Guidance
ComplianceRegulatoryInformation/Guidances/UCM073511.
pdf), and ICH Q10 entitled “Pharmaceutical Quality Systems”
published in April 2009 (http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/
UCM073517.pdf). Collectively, these guidelines were devel-
oped and designed to help create a science- and risk-
based approach to quality while encouraging continuous
improvement under an effective pharmaceutical quality
control system. By employing systematic approaches to
implement science and risk-based concepts provided in
these guidelines, throughout a product’s lifecycle, enhanced
pharmaceuticalproductqualityshouldbeachieved(seeProduct
Life Cycle figure below).
ICH Q8(R2)—Pharmaceutical Development
ICH Q8 encourages manufacturers to establish (dur-
ing design/development) detailed understanding about
their manufacturing process using QbD principles or other
alternative methodology, and to define appropriate design
space through assessment of process parameters that
might impact product quality. Based on this detailed un-
derstanding, manufacturers would be able to better assess
how future variation of critical material attributes and
process parameters within their ranges (design space)
could provide continuous assurance of product safety,
quality, and efficacy (http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatoryInformation/Guidances/
UCM073507.pdf).
ICH Q9—Quality Risk Management
Principles defined in ICH Q9 are intended to describe
development and use of systematic processes for the
assessment, control, communication, and review of quality
risks, throughout a product’s lifecycle (development, man-
ufacturing, and distribution; 2,3). The ICH Q9 guideline
recommendsidentification and utilizationofappropriatequality
risk management tools to ensure that product and/or process
changes are:
& based on scientific knowledge
& linked to patient safety and efficacy
& extended over the life cycle of the product
ICH Q10—Pharmaceutical Quality System
The principles described in ICH Q10 encourage manu-
facturers to identify, establish, and maintain a state of control
for process performance and product quality which will ulti-
mately help facilitate and control continual improvements and
potential changes to a product attribute and/or process param-
eter. Some critical elements described in ICH Q10 (http://
www.fda.gov/downloads/Drugs/GuidanceCompliance
RegulatoryInformation/Guidances/UCM073517.pdf; 3) include
& tracking and trending of product quality
& development, maintenance, and update of plans and/or
models as needed
& internal verification that product/process changes are
successful
Utilizing sound pharmaceutical development princi-
ples (ICH Q6 and Q8) in combination with a robust
product quality system (Q10) should provide opportunities
for flexible regulatory approaches to managing future
product and/or process changes for transdermal drug de-
livery systems.
Quality Target Product Profile and Identification
of Critical Quality Attributes
During development of a TDS, the development team
can benefit from creating a comprehensive Quality Target
Product Profile (QTPP) for the product. QTTP is a prospec-
tive summary of the quality characteristics of a drug product
that ideally will be achieved to ensure the desired quality,
taking into account safety and efficacy of the drug product
(http://www.fda.gov/downloads/Drugs/GuidanceCompliance
RegulatoryInformation/Guidances/UCM073507.pdf). It may
includethefollowingtargetelements:(1)intendeduseinclinical
setting, for example: route of administration, dosage form,
intended use period/conditions, residual drug, patient instruc-
tions/safety advice, and container closure system; (2) quality
attributes of the drug product, for example: physical attributes,
identity, strength, assay, uniformity, crystalline form/particle
s i z e ,p u r i t y / i m p u r i t y ,s t a b i l i t y ,m i c r o b i a lt e s t ,a n do t h e rc r i t i c a l
quality attributes related to a TDS product; (3) active pharma-
ceutical ingredient release or delivery and attributes affecting
220 Van Buskirk et al.pharmacokinetic characteristics; for example: dissolution and
permeation. For a TDS product, it is very important for the
development team to address all safety precautions that are
related to the use of the product.
A critical quality attribute (CQA) is a physical, chemical,
biological, or microbiological property or characteristic that
should be within limit, range, or distribution to ensure the
desired product quality (http://www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM073507.pdf). The selection of a CQA from quality attrib-
utes is based on its potential impact on patient safety and
efficacy. The product specifications and regulatory guidance
for TDS are a good start to determine a list of potential CQAs.
For a TDS product, the development team should specifically
consider additional attributes such as adhesion, cohesion,
leakage, cold flow, compatibility among all TDS components,
rate-controlling membrane (if used), and patch size/shape.
FDA’s Guidance—Residual Drug in Transdermal
and Related Drug Delivery Systems
The FDA’s Guidance on Residual Drug in Transdermal
and Related Drug Delivery Systems (4), finalized August
2011, recommends that an enhanced design and development
approach as described in ICH Q8 (R2) be used when devel-
oping and manufacturing TDS and other topical patches.
Some currently marketed TDS patches retain up to 95% of
the initial total amount of drug after the intended use period.
While it is understood that an excess amount of drug sub-
stance may be needed to facilitate delivery of the intended
amount of the drug to the patient, the amount of residual drug
substance in TDS patches has a significant potential to impact
the products’ quality, safety, and efficacy. Therefore, it is
necessary to ensure that an appropriate scientific approach is
used to design and develop these products to ensure that the
amount of residual drug substance is minimized consistent
with the current state of technology. The choice of formula-
tion, design, and system components may provide potential
pathways to optimize drug delivery and minimize residual
drug. Examples include, but are not limited to, the following:
& the use of penetration enhancers
& use of self-depleting solvent systems
& judicious choice of adhesive
Other factors may include the type and concentration of
excipients, drug load, adhesive thickness, and the composition
and thickness of the backing layer. The level of information in
the justification should be sufficient to demonstrate product
and process understanding and ensure that a scientific, risk-
based approach has been taken to minimize the amount of
residual drug in a system after use.
Utilization of IPEC Guidance
Independent of the ICH guidelines developed for APIs,
the International Pharmaceutical Excipient Council (IPEC)
has developed various guides targeted for use by excipient
manufacturers, handlers, distributors, users, and regulators
to ensure safety and performance of these materials and their
subsequent use in drug products.
Of special interest for TDS scale-up and post-approval
changes are IPEC guides that describe how excipient
suppliers can partner with their pharmaceutical customers
to ensure proper management and communication of cur-
rent excipient specifications and potential future changes
to their product (excipient) and/or its manufacturing process,
such as:
& IPEC Significant Change Guide for Bulk Pharmaceutical
Ingredients—establishes uniform considerations for evalu-
ating the significance of changes involving the manufacture
of pharmaceutical excipients while assessing the need to
inform excipient users and regulatory authorities about the
nature of the change (5).
& IPEC Qualification of Excipients for Use in Pharmaceuticals—
establishment of relationship between supplier and users by
concentrating on potential issues between the parties and offer-
ing examples of potential best practices for resolution (6).
& IPEC Quality Agreement Guide and Template—highlights
factors to consider when planning and executing quality
agreements (7).
& IPEC Excipient Information Package Guide—offers best
practice and guidance in the establishment of “standard”
excipient information packages intended to provide infor-
mation on excipient product regulatory datasheets as well as
overview of manufacturing site/supply chain security (8).
& IPEC QbD Guide (in development)—although currently
stillunderdevelopment,thisguideisintendedtoofferguidance
on the use and application of experimental methodology, such
as quality by design, in the development, commercialization,
and use of pharmaceutical excipients.
Improvements in the Characterization and Control
of Critical Excipients—Adhesives
The adhesive of the TDS is critical to the safety,
efficacy, and quality of the product. As noted in the
1997 SUPAC article, special attention is required of the
adhesive composition since it is in intimate contact with
the drug or other excipients that may alter either the
adhesive properties (mechanical characteristics) and/or
may influence the release of drug (extent and/or rate of
release). Adhesive parameters other than adhesive/drug inter-
actions that might influence drug release profiles could include
filler composition and the porosity, tortuosity (nonlinear
channeling), and thickness of the matrix layer. Improper
and/or poor adhesion of a transdermal patch could result
in improper patient dosing due to surface area reduction
and/or fall off; therefore, adhesion should be considered as an
important design parameter when developing transdermal
patches and for managing post-approval changes (8).
Three common classes of adhesives used in transder-
mal drug delivery systems include acrylic, silicone, and
synthetic rubber (e.g., polyisobutylene). The primary role
of the adhesive is to affix the transdermal system to the
skin. A secondary role could be to act as a carrier and/or
as a component of the formulation matrix for the drug.
Typically, the adhesive is laminated as a continuous adhe-
sive layer on the TDS surface; however, it could also be
only placed around the periphery or edges of the system.
Ideally, the selected adhesive is compatible with the drug
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to ensure acceptable mechanical characteristics (wear perfor-
mance) and drug delivery rates.
When making a post-approval change to an adhesive
used in a TDS, in addition to the obvious assessment of the
impact on the chemical stability of the dosage form, it is
beneficial to consider the impact of the change on such prop-
erties as: adhesive performance (adhesion, cohesion, tack),
functionality, adhesive monomer content and impurities, drug
and/or excipient solubility/stability, backing and/or release lin-
er compatibility, etc. These represent the common techniques
used in the developmental evaluation process and selection of
the optimum adhesive composition of the TDS. Also, it is
prudent to assess potential impact of the change on skin
irritation and or sensitization. When evaluating the impact
for changes in adhesive, it is advisable to consider whether
or not the test method used will assure lot-to-lot consistency/
quality, is stability indicating, is sufficiently discriminating to
detect changes that may influence product performance and is
reproducible (4). Adhesive performance characteristics often
considered as “critical quality attributes of adhesives” used in
TDS include adhesion, tack (or quick stick) and shear. Some
of the common test methods used to measure these critical
quality attributes, as well as other test methods often used to
characterize adhesive physical and/or chemical characteristics
can be found below.
Dry Adhesive (Bulk) Performance Testing
Historicaltestsusedtomeasureadhesiveperformance(peel
adhesion, tack, andshearstrength) were originally developed for
industrial pressure sensitive tapes and these tests are dependent
on substrates, backing materials, and test parameters
1.
& Adhesion—force to remove adhesive from a defined
substrate.
– Peel adhesion (PSTC 101, ASTM D3330/D 3330 M-04)—
force to remove adhesive from a rigid substrate such as
stainless steel
– Release force (PSTC 4)—force to remove an adhesive
strip from a release liner
& Tack—capacity of an adhesive to form a bond with another
surface after brief contact
– Thumb tack—perceived force to remove thumb from an
adhesive surface
– Rolling ball tack (PSTC 6)—measure of the capacity of an
adhesive to form a bond with the surface of another
material upon brief contact under virtually no pressure
– Probe tack (ASTM D2979-01)—force to remove adhesive
from an inverted probe under defined conditions (peak
force)
– Loop tack (PSTC 16)—force to remove a loop of adhe-
sive from a substrate (e.g., stainless steel) under defined
conditions (peak force)
– Texture Analyzer “tack”—f o r c et or e m o v eap r o b e
from an adhesive under defined conditions (peak
force and area under curve)
& Shear strength—measure of the internal or cohesive strength
of an adhesive film
– Static shear (PSTC 107, ASTM D 3654/D 3654 M-06)—
ability of a tape to resist static forces applied in the same
plane as the backing
– Dynamic shear—“peak load” or “yield stress” of adhe-
sive strip adhered to untreated polyester using tensile
equipment/test method
& Rheology—measure of the visco-elastic properties (defor-
mation and flow) properties of a material
One additional test that is useful to measure residual
solvent and/or monomers in bulk adhesives is GC headspace
analysis.
Wet Adhesive (Solution) Performance Testing
Other tests that are often performed to evaluate the
impact of an adhesive change on the identity, composition,
and/or physical properties of a transdermal drug delivery
system include:
& Identity—fingerprint of chemical identity
& Appearance—visual examination for defined characteristics
& Nonvolatility or % solids—determination of final concen-
tration of the adhesive solids
& Viscosity—measure of shear thinning and/or resistance of a
liquid to flow
– Rotational “dynamic” viscosity—measure of the non-
Newtonian, shear thinning property of a liquid
– Relative “kinematic” viscosity—measure of the resistive
flow of a fluid under the influence of gravity
Pressure Sensitive Adhesive Performance. It is appropri-
ate to evaluate bulk pressure sensitive adhesive (PSA) perfor-
mance for any changes made to an adhesive used to produce
drug-loaded patches since changes in the adhesive could also
result in changes in stability or performance of the final TDS.
In order to ensure acceptable adhesive quality/safety, it is
also critical to evaluate the impact of the change of PSA
on subsequent TDS process steps (e.g., blending, laminat-
ing, cleaning) and final product performance (mechanical
properties, stability, drug release profile, toxicity, etc.).
Post-approval changes in the adhesive can change the bioavail-
ability and/or bioequivalence (BA/BE) in products that depend
on the adhesive to be the release matrix, so, the drug product’s
bioequivalence may have to be reassessed.
Improvements in the Characterization and Control
of Critical Excipients—Rate-Controlling Membranes
2
Rate controlling membranes (RCM) serve two primary
functions within a TDS. The RCM places a limit on the
maximum delivery rate of the drug from the system and it is
also a structural component of the system. Typically, the RCM
does not come into direct contact with skin. As a structural
component of the complete transdermal system it is essential
1 References to Pressure Sensitive Tape Council methods are provid-
ed in the “Glossary” to this whitepaper
2 Backing films and release liners are not considered rate controlling
membranes and are therefore dealt with separately within this
document.
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above and below it during wear and removal. Ideally the
RCM possesses an appropriate level of flexibility to avoid a
detrimental impact on system comfort and wearability.
The two broad classes of materials used as RCM can be
divided into homogenous polymer films and films with pores
in the micro- and nanometer range. Delivery rate control is
achieved by the diffusion rate across a homogenous film
or by transport across a film with a defined number and
size distribution of pores.
Suitable materials for the RCM include the wide array of
polymer films and fabrics used in various skin contact appli-
cations. It is desirable that the RCM candidate materials do
not contain any leachable irritating or sensitizing compounds.
RCM materials are often selected from suppliers producing
materials originally for different applications. Therefore, the
TDS formulator may wish to carefully compile a list of RCM
physical and chemical properties desired for the RCM to func-
tionasdesigned.Itislikelythat thevendorcertificateofanalysis
maynotcontainadequatedatatoensuretheperformanceofthe
RCM and additional characterization may be needed.
PAT Approaches
As noted in the previous section, the use of QbD is
critical in the development of pharmaceutical products and
processes. The focus of QbD is defining a design space for
critical process parameters to ensure that CQA’sa n dt h e
overall QTPP are continuously met. To help ensure this is
done repeatedly in commercial operations, FDA issued a
guidance document for industry in September 2004 that was
entitled, “PAT—A framework for innovative pharmaceutical
development, manufacturing and quality assurance” (9). The
goal of using PAT is to understand and control the manufactur-
ing process, which is consistent with FDA’s current drug quality
system recommendations. The system states that quality cannot
be tested into products; it should be built-in by design.
As defined by FDA, process analytical technology is:
& a system for designing, analyzing, and controlling man-
ufacturing through timely measurements (i.e., during
processing) of critical quality and performance attributes
of raw and in-process materials and processes with the
goal of ensuring final product quality
It is important to note that the term analytical in PAT
is viewed broadly to include chemical, physical, microbio-
logical, mathematical, and risk analysis conducted in an
integrated manner.
This section of the paper will discuss the use of PAT in the
manufacture of TDS. PAT can be used through development,
scale-up, and commercialization. In addition, some of the
generated data can be used to scientifically justify post-
approval CMC changes.
As noted in the 1997 Paper, “Scale-Up of Adhesive
Transdermal Drug Delivery Systems”, the manufacture of
transdermal delivery systems typically involves several unit
operations. A summary of these are described below.
& Liquid blending—Drug, excipients, and polymers are blend-
ed together. Drug-in-adhesive (e.g., “matrix”) TDS require
the blending of the drug into the adhesive. The “reservoir”
TDS does not blend the adhesive, but rather blends the drug
with the excipients. This liquid is then placed in the reservoir
on the finished patch.
& Coating, drying, and laminating—In matrix TDS, the blend
is coated onto a substrate (film) and the solvent used in the
adhesive is dried and removed from the patch to meet ICH
limits. Upon exiting the dryer, another substrate (film) is
laminated on top of the dried adhesive before it is wound
into a roll.
& Filling, laminating, and sealing—In reservoir TDS, the blend
is filled onto a substrate (typically a multilayer film with the
skin contact adhesive attached to it), laminated with a sub-
strate (film) and sealed together.
& Die-cutting and pouching—After the coating, drying, and
laminating (matrix TDS) or filling, laminating and sealing
(reservoir TDS), the final part is die cut to the pre-deter-
mined size and shape. The finished dosage form is then
placed into a primary package prior to the secondary carton.
Each of these unit operations has critical process param-
eters (CPPs) that can impact the CQA of the product. The
following sections explain how process analytical technology
can be used to ensure real-time monitoring and control of the
CQA.
Control Approaches for Development
During product development activities, the formulation
scientist develops a product through measuring critical quality
attributes. Often the methods used during development are
just preliminary. In that manner, many of the tests have long
run times and limited accuracy. They are used as a means to
screen formulations before more robust monitoring is put in
place. As products move forward through animal pharmaco-
kinetic (PK) and subsequently human PK studies, the method
robustness is improved dramatically. The data acquisition and
monitoring is typically done in offline, batch-type processing.
Given the relatively small number of batches, this approach is
appropriate as long as CQAs are properly identified and can
be passed to the next phase of development.
Control Approaches for Scale-Up and Commercialization
As products move into the later stage clinical work, the
process scale-up work is initiated. The scale-up work begins in
an effort to develop a process that will yield a product that
meets the CQAs identified during initial product development
activities. Given the significantly larger clinical investment as
the product moves past the preliminary clinical studies, PAT
has advantages in the identification and control of CPPs and
the operating ranges for the process parameters that ensure
the CQAs identified during product development are met.
TDS have a combination of batch and continuous processes
that enable the use of PAT for one or more manufacturing
operations.
Designed experiments can be used to correlate CPPs to
CQAs. Due to the large number of variables that can impact
the CQAs of TDS, the designed experiments typically start
with screening studies. These do not identify single variables
or independent interaction effects that may impact a CQA,
but rather they provide directional information for further
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torial design of experiments (DOE). The full-factorial DOE
approach takes the most significant factors from the screening
studies and then works to identify which factor(s) have prima-
ry and interaction effects on the CQAs. As the most signifi-
cant CPPs are identified, it can be beneficial to look to identify
ways to use PAT approaches to analyze and control these
CPPs. The ultimate goal is to use validation data to conclu-
sively show the linkage of a CPP to a CQA of the finished
drug product. The section below walks through each major
unit operation in TDS and where PAT may be used.
& Liquid Blending
– Critical Process Parameters—PAT can be used to analyze
and control liquid blending. Typically the process inputs
that are identified as CPPs are product temperature, agita-
tion speeds, and agitation times. To ensure real-time mon-
itoring of these parameters, systems exist that can report
actual values at a predetermined intervals. It is important
to understand the design space in these applications and
understand what intervals should be monitored.
– Critical Quality Attributes—PAT can be used to monitor
inputs, as well as product outputs. In blends, CQAs typi-
cally include drug identification/content, product viscosity,
appearance and sometimes particlesize.Withthe advance-
ment in technology, there are many available tools to
monitor these CQAs including in situ Fourier transform
infrared spectroscopy for monitoring complex liquid
blend reactions, in-process video microscopy or laser-
based detection systems to monitor particle size or
inline and intank viscometers that can provide real-
time viscosity measurement.
& Coating, Drying, and Laminating
– Critical Process Parameters—PAT can be used to analyze
and control coating,drying,andlaminating processes. Typ-
ically, the process inputs that are identified as CPPs are
dryer temperatures,dryer airflow/exhaust, line speed,and/
or pump speed. These CPPs can be monitored using data
collection software. As with liquid blending, it is important
to understand the design space in these applications and
understand what intervals are required to be monitored.
– Critical Quality Attributes—In coating, drying, and lami-
nating operations, the CQAs that could be monitored
include product web temperature, product thickness,
and drug/excipient identification and/or assay. Infrared
sensors can be used in these applications including web
thickness and moisture sensing equipment that monitor
product attributes as the web moves through the system.
In drying operations, product web temperature is often a
critical attribute that can signal process upsets. The web
temperature is a key factor in the drying rate of the adhe-
sive. If dryer set points or air flows are not functioning as
designed, the product web temperature can help identify
this issue in real-time to enable in-process adjustments.
& Filing, Laminating, and Sealing
– Critical Process Parameters—PAT can be used to analyze
and control filling, laminating, and sealing processes.
Typically, the process inputs that are identified as CPPs
are fill volumes, sealing station temperature, time, and
pressure. These parameters could be monitored real-time
through data collection software. Identification of re-
cording intervals can be critical to maximize value.
– Critical Quality Attributes—CQAs that could be moni-
tored include fill weight, seal integrity/seal strength, drug/
excipient identification/and assay, and liquid presence.
Gel or liquid presence can be monitored online through
the use of vision systems.
When designed and validated, the vision systems can be
tied into rejection systems such that TDS without liquid are
automatically rejected. Fill weight drives the drug/excipient
assay and its on-line monitoring can be done through the use
of check-weigh systems. With these systems though, it is
imperative that the system be properly designed to ensure it
can handle material variations. TDS typically have low fill
volumes so ensuring that systems are designed to properly
tare material is critical to ascertaining quality without false
positives for fill weight events. In addition to fill weight, the
importance of seal integrity and seal strength to reservoir TDS
is well documented. In fall 2010, the USP published a draft
revision that was heavily focused on leak control of TDS and
topical systems (10). The draft suggested that 100% online
leak detection systems could be implemented and that if that
is not possible, significant offline monitoring should be uti-
lized. PAT can be implemented to test 100% of patches for
leakage.
& Die Cutting and Pouching
– Critical Process Parameters—PAT can be used to analyze
and control die cutting and pouching process. Typically
the process inputs that are identified as CPP are web
tension, die and sealing station temperatures, time, and
pressure. Data collection software can be used to moni-
tor these process inputs.
– Critical Quality Attributes—In the unit operation used to
cut the TDS, shape and place it in its primary package,
the process outputs of size, pouch seal integrity/strength,
and drug/excipient identification/assay could be moni-
tored. Online vision systems can be validated to reject
any TDS that does not meet size specifications. Because
surface area is critical to drug delivery with TDS, these
systems can help ensure that the proper size units are
packaged. Though less critical than with reservoir sys-
tems, online mechanisms for the monitoring of pouch
seal integrity/strength are also available.
The information collected through PAT is valuable,
but only if used properly. In addition to collecting the
data in each key unit operation, it is critical that systems
be put in place to properly monitor and review the data.
It is also recommended that groups using this data be
given the training and tools to be autonomous in the
decision-making related to reacting to the data. In addi-
tion to real-time reporting, it is recommended that the
data be presented in a manner so that trends can be
identified and monitored to prevent problems before they
occur.
Using PAT to Justify SUPAC Changes
Process, Equipment or Site Changes. Most FDA guidance
for changes to an approved drug product post-approval typi-
cally state that in vitro comparisons, stability testing, and
possibly in vivo clinical studies are required for some changes.
The use of process analytical technology can help support the
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manufacturing parameters, equipment, or sites. Through the
use of regulatory mechanisms, such as comparability proto-
cols, it may be possible to reduce the reporting requirements
for these changes.
PAT can also support process or equipment changes
and minimize potential adverse effects on product CQAs
For example, if a blend is being scaled up to a larger size,
the inline viscosity, appearance, and/or particle size data
can provide meaningful support for process comparisons.
Similarly, the monitoring of product web temperature and
product thickness in coating, drying, and laminating oper-
ations can provide meaningful data to help justify product/
process equivalence.
Product and Process Validation
Process validation requirements for the TDS are
expected to focus on important principles that affect product
quality. Upon installation and qualification of all the manufac-
turing equipment, the product development information cap-
tured in the development pharmaceutics report and during
execution of process qualification batches will be pivotal to
the design and execution of the product/process validation
protocol. The PAT tools referenced earlier also provide good
tools to help prove process robustness during the execution of
process validation. The current approach to TDS validation is
similar to oral dosage forms and consists of: (1) development
work that establishes the anticipated manufacturing targets,
(2) manufacture and testing of validation batches demonstrat-
ing adequacy of in-process and finished product control crite-
ria and overall product quality, and (3) periodic confirmation
of product consistency during the product life cycle as well as
tracking/trending for early detection of problems.
Some of the key processing steps and parameters to
consider in the validation protocol are:
Solutions Manufacture (drug-containing or drug-free)
& mixing equipment design specifications, order of addition,
mixing speed, mixing time
& open or closed vessel
During development and scale up it may be beneficial to consider
component changes either by the developer or raw material
suppliers.
Coating of drug-containing or drug-free matrix layers
& machine speed
& temperature settings in each drying zone
& air flow rate in each drying zone
Also consider die design changes—number of lanes, gap, etc.…
Slitting
& machine speed
& cutting width
& roll tension
Also consider equipment changes—e.g., knives—fixed slitting
blades vs. rotary knife
Punching/pouching
& Machine speed
& Pouch sealing temperature
& Pouch sealing pressure
& Optical/vision systems for detection of all applicable
functions
The above items are the most widely used steps in the
manufacture of matrix TDS. Reservoir type products would
include similar steps except for the fabrication step which
typically requires validation of the following additional steps:
Optical/vision systems (used in the in-process control of TDS
production)
Fabrication/pouching
& Machine speed
& Patch sealing temperature, pressure, and dwell time
& Pouch sealing temperature
& Pouch sealing pressure
Finished Product Testing—Product Quality Tests
The product quality attributes typically include: description,
identification, assay (strength), impurities, uniformity of dosage
units, residual solvent levels, creep resistance (cold flow property),
mechanical properties, microbial limits, pouch seal integrity, and
other tests that may be product specific. Some product quality
attributes such as coating weight, residual solvents, and pouch seal
integrity are commonly tested in-process. It is desirable that phys-
ical tests are quantitative and have minimum and maximum ac-
ceptance criteria, where applicable. Product performance testing
assesses drug release and other attributes that affect drug release
from the finished dosage form. Several product performance tests
are available to assess in vitro drug release from TDS (11).
Description. The qualitative description of the drug product
and packaging. It typically includes a visual examination of the
patch to identify the shape and size dimensions, changes in color,
adhesive migration that are specific to the drug product and
appearance of the packaging including the content or the label
claim of the article.
Identification. Identification tests establish the identity of
the drug or drugs present in the article and discriminate be-
tween compounds of closely related structures that are likely
to be present.
Assay. A specific and stability-indicating test used to de-
termine the strength (content) of the drug product.
Impurities. This test assesses process impurities, synthetic
by-products, residual solvents, elemental impurities, and other
inorganic and organic impurities that may be present in the
drug substance and excipients used in the manufacture of the
drug product and those arising during the manufacturing pro-
cess of the drug product.
Uniformity of Dosage Units. This test is applicable for all
TDS to evaluate intrabatch consistency.
Uniformity of Content within the Patch. An appropriate
test can assure that there is no migration of API from the
active portion of the patch to any of the patch components
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throughout the TDS.
Polymorphism. It can be essential during development of
a TDS to determine if any polymorphic changes to the drug
substance can occur during the manufacturing process or dur-
ing the shelf life of the product. In addition, it is advisable to
check for polymorphic changes due to changes in the formu-
lation, manufacturing process or packaging of the TDS.
Residual Solvent Levels. The levels of residual solvents
can be tested per ICH Q3C (R4) Impurities: Guideline for
Residual Solvents (http://www.fda.gov/Drugs/Guidance
ComplianceRegulatoryInformation/Guidances/ucm125820.
htm; http://www/fda.gov/downloads/Drugs/Guidance
ComplianceRegulatoryInformation/Guidances/UCM073395.
pdf). Ideally residual solvents of TDS aresufficiently low sothat
they do not pose a safety concern nor impact the functional and
performance properties of the TDS.
Creep Resistance (Cold Flow Property). Cold flow is a
unique aspect of pressure sensitive adhesives that manifests
itself through adhesive migration out of the edge of the patch
during storage or when the patch is applied to the patient.
Excessive cold flow can lead to adhesive sticking to the inside
pouch surfaces, which may lead to a reduction in drug potency
and inadvertent separation of the liner during patch removal
from the pouch. Excessive cold flow can also lead to appear-
ance of a “dirty ring around the patch” upon application to the
skin of the patient leading to product esthetic complaints.
Clothing adherence to the adhesive creep serves to magnify
patient complaints.
Adhesion Evaluation Test. Three types of TDS adhesion
tests are generally used to evaluate adhesive properties of the
drug product: Peel Adhesion Test (from a standard substrate),
Release Liner Peel Test, and Probe Tack Test. The peel ad-
hesion test and release liner test assess two different TDS drug
product attributes. Adhesion test acceptance criteria are prod-
uct specific and are typically defined generally to assure that
adhesion of each batch of TDS is within the range defined by
the product design and is consistent between batches based on
the product development specifications and statistical assess-
ment of multiple product batches over the product’s shelf life
or wear studies. Ideal adhesive characteristics in TDS permit
easy removal of the release liner before use, adhere properly
to human skin upon application, maintain adhesion to the skin
during the prescribed period of use, permit easy removal of
the TDS at the end of use without leaving a residue or causing
damage to the skin or other undesirable effect(s) and maintain
the performance of the TDS throughout the shelf life of the
drug product.
Peel Adhesion Test. This test measures the force required
to remove (peel away) a TDS attached to a standard substrate
surface (usually polished stainless steel). The TDS is applied
to the substrate using specified techniques for application and
is conditioned at specified temperature and time. Then, the
TDS is peeled away from the substrate with an instrument that
allows control of peel angle (usually 90° or 180°) and peel rate
(usually 300 mm/min), and the peel force is recorded. This
procedure is typically repeated using a minimum of five inde-
pendent samples.
Release Liner Peel Test. This test measures the force
required to separate the release liner from the adhesive layer
of the TDS. The test is typically performed with a finished
product sample. The test sample is conditioned using specific
procedures (temperature and time). Then the release liner is
pulled away from the TDS with an instrument that allows for
control of peel angle (usually 90° or 180°) and the peel rate
and peel force are then recorded. This procedure is typically
repeated using a minimum of five independent samples.
Probe Tack Test Method. This test measures the force
required to separate the tip of the test probe from the adhe-
sive layer of the TDS. This test employs an instrument
designed to create a bond between the tip of a test probe of
defined roughness and the TDS using a controlled force (light
pressure) and specified test conditions (i.e., rate, contact time,
pressure). Then, while controlling the rate of probe removal,
the test measures the profile of force required to separate the
probe tip from the TDS and the maximum force required to
break the bond (tack).
Rolling Ball Method. This test measures the distance
traveled by a defined weight (ball) across the adhesive layer
of the TDS under defined conditions (12). The resulting mea-
surement is a parameter dependent on the tack properties of
the adhesive layer.
Water Content. A test for water content is appropriate for
some TDS, e.g., for hydro-alcoholic reservoir type patches.
Antioxidant Content. Evaluation of the antioxidant con-
tent in the drug product can help assure the levels of antiox-
idant necessary to maintain the product’s stability at all stages
throughout its proposed usage and shelf life.
Particle Size. Particle size testing is relevant when the
drug substance is designed to be suspended in the TDS. The
test typically includes examination for evidence of particle size
alteration (i.e., appearance of particles, changes in particle
form, size, shape, habit, or aggregation) of the active drug
substance that may occur during the course of product pro-
cessing and storage.
Crystal Formation Test. When a TDS does not contain
suspended API, but rather, dissolved API, it is recommended
that the potential of formation of crystals during storage (e.g.,
due to change of crystal form of the amorphous drug substan-
ces) be evaluated during product development. Multiple
approaches including a crystal seeding study may be useful
for this purpose.
Leak Test. This test is applicable to form-fill-seal (liquid
reservoir) type TDS and certain matrix TDS. A leak test can
help assure that form-fill-seal patches are manufactured with
zero tolerance for leaks because of their potential for dose
dumping if leaking occurs. In-process control methods can
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manufacturing process can also be evaluated for the presence of
leakage, or potential for leakage due to patch perforation, cuts,
faulty seals, or other factors. These leaks may result from fail-
ures such as air bubbles, gel splash or misalignment of a patch’s
backing andrelease liner layers. PATandin-process testing may
be beneficial to identify these defects.
Finished Product Leak Test (aka Pouch Integrity Test). A
pouch integrity test may be useful for all TDS to evaluate leaks
that may have occurred after the TDS are manufactured and
packaged in their primary packaging material and on stability.
Microbial Test. The microbial integrity of the TDS is
important. Some TDS formulations will not support microbial
growth; however, assurance data from development can be
useful to reconfirm this if any post approval changes to the
TDS or TDS package are made.
Product Performance Test (In Vitro Drug Release)
In vitro drug release methods for transdermal delivery
systems include the use of Apparatus 5 (Paddle over Disk
Method), Apparatus 6 (Rotating Cylinder Method), and Ap-
paratus 7 (Reciprocating Holder Method) as described in USP
34/NF29, General Chapter <724>Drug Release (11).
Finished Product Testing—Product Quality Tests (Current
IVIVC Considerations)
Background
Historically, IVIVC analyses have been applied to ex-
tended-release solid oral dosage forms. An IVIVC describes
the relationship between the in vitro performance (e.g., disso-
lution) and the in vivo characteristics (e.g., plasma drug con-
centrations or derived pharmacokinetic parameters such as
Cmax or area under the curve, AUC) following administration
of the dosage form. Ideally, an IVIVC is a quantitative relation-
shipwhichpredictsdrugconcentrationsfrominvitrodissolution.
The pharmacokinetics and in vitro/in vivo relationships of trans-
dermal (systemic drug administration) and topical (locally act-
ing) drugs, are more complex than for oral drug products.
Although in vitro dissolution of solid oral dosage forms may be
correlatedwithinvivoperformance(pharmacokinetics),inmost
cases, the use of dissolution for transdermal or topical dosage
formsislimitedto being aqualitycontrolmeasure.Thecomplex
mechanism of permeation of drugs across epidermal layers of
skin cannot possibly be replicated using dissolution methods.
Therefore, other in vitro methods such as flux studies using
Franz cells with excised human skin may be useful to assess in
vitro performance of transdermal and topical dosage forms dur-
ing product development (13–15).
Most transdermal dosage forms are designed to deliver
drug molecules to the systemic circulation. Thus, plasma con-
centrations can be measured. However, systemic concentra-
tions observed after application of locally acting, topical
dosage forms (e.g., TDS) may not be relevant and clinical
trials are typically needed to establish BE. Although topical
products provide high concentrations of drug at the local site
of action (the dermis), the concentrations in blood are often
too low to measure and/or may not be predictive of the topical
efficacy; accordingly, it is recommended that systemic expo-
sure be assessed when there is risk of systemic adverse reac-
tions (16). With the advent of new and very sensitive analytical
methods, it may now be possible to measure systemic concen-
trations of some drugs after topical administration. However,
one should not confuse the ability to measure systemic concen-
trations with the ability to measure or predict efficacy. In the
absence of PK/PD data showing relevance of plasma concentra-
tion to effect, the ability to measure systemic levels after topical
applications may not correlate with a local effect (efficacy).
In Vitro Drug Release (Dissolution) Versus In Vitro Permeation
Cells (e.g., Franz cells)
In vitro drug release profiles can be assessed using estab-
lished methods. In vitro drug release testing is traditionally
used as a quality control tool. The contents of patches are
tested by release into an appropriate sink medium within
timeframes that may or may not have physiological relevance.
Most TDS are manufactured to deliver their contents over
24 h or longer, although the content may be released relatively
more quickly when evaluated using in vitro dissolution.
Dickenson et al.( 17) described several important aspects
needed to ensure that dissolution methods are relevant for the
following purposes:
1. To distinguish among different processing and formu-
lation variables, and
2. To complete dissolution within a timescale appropriate
for a routine control test.
Dickenson’s criteria are equally relevant to in vitro per-
meation studies.
General Considerations for Use inDeveloping an IVIVC for TDS
The following general concepts as described in the IVIVC
guidance for Extended Release Dosage Forms (18) are gener-
ally applicable to TDS with some necessary modifications.
& In vivo human data from sufficient subjects (a statistically
powered sample) are preferred for IVIVC correlations to
statistically differentiate between Cmax values obtained for
different formulation used in a clinical study.
& Crossover studies are preferred, but appropriate powered
parallel studies may be acceptable.
& To correlate in vitro drug release/dissolution data, the same
validated and reproducible in-vitro drug release/dissolution
method is preferred to be used for assessing all transdermal
formulations in the IVIVC.
& Because of inherent variability in absorption between individ-
uals and between anatomical sites (e.g., abdominal versus
forearm skin), it is important to control for skin source and
viability and to evaluate in vitro permeability across skin from
several donors in cases where in-vitro skin permeation data is
correlated.
Categories of In Vitro/In Vivo Correlations
The categories for IVIVCs for transdermal products can
be classified the same as those identified for oral drug
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for transdermal IVIVC, level B (which uses mean dissolution
time) and level C categories are probably not applicable to
transdermal dosage forms.
Level A Correlations
Level A IVIVC correlations provide the strongest
evidence that a quantitative relationship exists between
in vivo absorption and in vitro drug release. The in vivo
absorption–time curve may be determined using classical
techniques such as Wagner–Nelson or Loo–Riegelman
methods or may be estimated using numerical deconvo-
lution. Ideally, the in vitro and in vivo input rate curves
are superimposable; if not, a scaling factor may be used
to improve the superimposability. Alternatively, the in
vitro and in vivo data may be modeled to develop a
relationship that predicts plasma concentrations based
on in vitro dissolution/release rates. For each of these
modeling techniques it is critical that the in vitro data
predict the entire in vivo concentration versus time
profile.
An important advantage of a level A correlation is that,
since an in vitro dissolution/release curve is used as a surrogate
for in vivo performance, changes in manufacturing conditions,
raw material suppliers or minor formulation alterations may
be justified on the basis of in vitro data, rather than in vivo
bioavailability studies.
Level B Correlations
This correlation utilizes the principles of statistical
moment analysis, although, not easily applicable to trans-
dermal products. The mean in vitro dissolution or release
time is compared to either the mean residence time or the
in vivo mean dissolution time. Even though level B cor-
relations utilize all of the in vitro and in vivo data points,
they do not provide point-to-point correlations and do not
correlate the actual in vivo plasma profiles. The weakness
in this approach is that it is possible for different plasma
concentration-time profiles to produce similar mean resi-
dence time values. Thus, it is not possible for a level B
correlation alone to predict a plasma profile from in vitro
dissolution data.
Level C Correlations
The level C IVIVC relates a single point relationship
between in vitro dissolution or drug release parameters (e.g.,
the time to 50% dissolution or release) to a single pharmaco-
kinetic parameter such as AUC or Cmax. This single point
correlation does not reflect the complete shape of the plasma
profile, which best defines the in vivo performance of trans-
dermal products. Since this type of correlation is not predic-
tive of actual in vivo product performance, it has limited utility
but may be useful as a guide in formulation development.
Overall, considerations for the development of an IVIVC for
passive TDS should follow the same steps outlined for oral
drug products from development, validation, and predictabil-
ity aspects (18).
IVIVC for Locally Acting Transdermal Drug Products
In 2001, Shah published “Progress in Methodologies for
Evaluating Bioequivalence of Topical Formulations
” (19). He
described three areas which require addressing in order to
have confidence in the ability of DPK methodology to
predict topical bioequivalence. These areas are also quite
relevant to develop confidence that systemic drug
concentrations are related to a topical (skin) clinical effect.
These three areas are:
& relevance to clinical efficacy
& ability to differentiate between strengths and formulations
& reliability and reproducibility
Recently, the agency has published a draft Guidance
for Topical Lidocaine Patches (20). It allows a BE study
which relies on systemic blood levels to be used. To date,
there have been few publications which have described a
relationship between in vitro release data and in vivo
blood levels for either transdermal or topical products
(14,15,21) .T h ed i f f i c u l t ym a yl i ei nf o r m u l a t i n gt h e s e
products with different rates of release; however, this
does not preclude the validation of IVIVC in the near
future.
The Future of TDS Development
As noted earlier, the authors foresee the introduction of a
large array of transdermal delivery systems that utilize
“active transport” approaches to improving drug flux of
compounds that heretofore were not able to be delivered
by the traditional passive TDS platforms. The approaches
to non-passive transport include, but may not be limited
to, electrophoresis, electroporesis, needle array systems,
facilitated transport in the presence of specialty additives
or complexing agents, high pressure microjet transport,
and transport across compromised or abraded skin. These
approaches hold great promise for delivery of peptides,
proteins and other previously unsuccessful drug candidates
(due to poor flux or low potency). An additional aspect to
the future development of TDS involves nanoparticulate
forms of APIs. Such nanoparticulates may undergo suc-
cessful, substantial follicular uptake, and provide for a
more extended residence time in the skin in contrast to
more conventional forms. While much of the information
on product development and scale-up remains the same as
their passive-molecule counterparts, there are unique
aspects to both the delivery system and the delivered
drugs that warrant a separate discussion and consideration
of development and change management issues. There-
fore, the authors propose to review scientific and regula-
tory principles of nonpassive TDS at some time in the
future.
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Glossary of Selected Terms and Test Methods Used in this Paper
Change Control A process used for management review of
proposed changes that may impact thequality orregulatory
conformance of the excipient (5).
Critical Excipient Any material that can increase, decrease or
change the profile of drug release in the TDS (1).
Critical Process Parameters (CPP) A process parameter whose
variability has an impact on a critical quality attribute and
therefore should be monitored or controlled to ensure the
process produces the desired quality (2).
Critical Quality Attributes (CQA) A physical, chemical, bio-
logical or microbiological property or characteristic that
should be within an appropriate limit, range, or distribution
to ensure the desired product quality (2).
Design Space The multidimensional combination and interac-
tion of input variables (e.g., material attributes) and process
parameters that have been demonstrated to provide assur-
ance of quality. Design space is proposed by the applicant
and is subject to regulatory assessment and approval (ICH
Q8) (2).
Excipient Substances other than the API which have been
appropriately evaluated for safety and are intentionally
included in a drug delivery system (5).
ICH International Conference on Harmonization (2).
Loop Tack A measure of the force required to separate the
adhesive from the adherent at the interface shortly after
theyhavebeenbroughtintocontactunderaloadequalonly
to the weight of the pressure sensitive article (e.g.,t a p e ,
label, sticker, etc.) on a one square inch contact area (22).
Peel Adhesion See definition provided previously (23).
Process Analytical Technology A system for designing, analyz-
ing, and controlling manufacturing through timely measure-
ments (i.e., during processing) of critical quality and
performance attributes of raw and in-process materials and
processes with the goal of ensuring final product quality (9).
Quality by Design The development of the design space, spec-
ifications, and manufacturing controls that result from phar-
maceutical development studies using Design of
Experiments, process analytical technology (PAT) and or
prior knowledge (7).
Release Force The measure of the force required to separate a
unit width of pressure sensitive tape from a release liner at
controlled angle and speed (24).
Residual Solvents Residual solvents are defined as organic
chemicals that are used or produced in the manufacture of
active substances or excipients, or in the preparation of
medicinal products (8).
Rolling Ball Tack See definition provided previously (25).
Shear Ability of a tape to resist static forces applied in the same
plane as the backing (26).
Significant Change Any change that alters an excipient physical
or chemical property from the norm, or that is likely to alter
the excipient performance in the dosage form (5).
Relevant List of PSTC Adhesion Test Methods
PSTC-101 InternationalStandardforPeelAdhesionofPressure
Sensitive Tape—ISO Approved
PSTC-4 Relative Performance of Release Coatings
PSTC-5 Quick Stick of Pressure Sensitive Tapes
PSTC-6 Tack Rolling Ball
PSTC-107 International Standard for Shear Adhesion of Pres-
sure Sensitive Tape—ISO Approved
PSTC-8 Unwind Force of Pressure Sensitive Tape
PSTC-9 Accelerated Aging of Pressure Sensitive Tape
PSTC-11 Adherence to Linerboard of Pressure Sensitive Tapes
at Low Temperature
PSTC-13 High Speed Unwind Adhesion of Pressure Sensitive
Tapes
PSTC-14 Adhesion of PressureSensitive Tapes to Fiberboardat
90° Angle and Constant Stress
PSTC-15 Determination of Adhesion to Release Coated Sub-
strates: Wet Spread Method
PSTC-16 Loop Tack
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